21420-36-0

Basic information

• Product Name: CYANAMIDE, [14C]
• Synonyms: CYANAMIDE, [14C]
• CAS NO: 21420-36-0
• Molecular Formula: CH₂N₂
• Molecular Weight: 44.06
• Mol File: 21420-36-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: CYANAMIDE, [14C](CAS DataBase Reference)
• NIST Chemistry Reference: CYANAMIDE, [14C](21420-36-0)
• EPA Substance Registry System: CYANAMIDE, [14C](21420-36-0)

Safety Data

• Hazardous Substances Data: 21420-36-0(Hazardous Substances Data)

Upstream product

• 7664-41-7 ammonia 
• 1882-53-7 barium [14-C]carbonate 
• 77874-59-0 (14C)Cyanogen bromide 

Downstream Products

• 5022-68-4 <(14)C>thiourea 
• 917358-59-9 N-(2-methyl-5-nitro-phenyl)[⁽¹⁴⁾C]quanidine 
• 594-05-8 [¹⁴C]urea 
• 1203588-95-7 4-(⁽¹⁴⁾C-guanidino)benzoic acid hydrochloride 

Relevant articles and documents

Synthesis of [14C] labeled 2-methoxypyrimidine-5-carboxylic acid

A versatile method for 14C labeling of 2-methoxypyrimidine-5- carboxylic acid at the 2-position has been developed after encountering difficulties with traditional approaches to label the carboxyl function. The method developed can also be used for 14C labeling other positions of the pyrimidine ring system. Copyright

Syntheses of 3H-labeled, 14C-labeled, and 2H4-labeled SCH 444877, phosphodiesterase type 5 inhibitors

The syntheses of [3H]SCH 444877, [2H4]SCH 444877, and [14C]SCH 444877 are described. [3H]SCH 444877 was prepared in three steps from tritium gas. [2H4]SCH 444877 was synthesized from [2H4]ethanolamine in four steps with an overall yield of 40%. [14C]SCH 444877 was prepared from barium [14C]cyanamide in 10 steps with an overall yield of 8.1%. Copyright

METHODS AND INTERMEDIATES FOR THE PREPARATION OF OPTIONALLY RADIO-LABELED IMATINIB

The invention relates to new processes for the manufacture of N-{5-[4-(4-methyl-piperazino- methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine of formula (I), new processes for the manufacture of metabolites of N-{5-[4-(4-methyl-piperazino-methyl)- benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine observed after administration of the compound to warm-blooded animals as well as to intermediates used in said processes. New starting materials as well as processes for the preparation thereof are likewise the subject of this invention. The processes described herein are especially suitable to furnish said compounds having isotopic labeling. The such obtained labeled compounds are in particular suitable to track and to investigate into the metabolism of N-{5-[4-(4-methyl- piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and its pharmaceutically acceptable salts in clinical and pre-clinical studies.